- ISIN
- CA05156V1022
- CUSIP
- 05156V102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 26, 1999
Highlights
- Market Cap
- $1.91B
- Enterprise Value
- $1.96B
- EPS (TTM)
- $2.17
- PE Ratio
- 6.86
- PEG Ratio
- 0.00
- Total Revenue (TTM)
- $298.30M
- Gross Profit (TTM)
- $267.70M
- EBITDA (TTM)
- $153.45M
- Year Range
- $10.34 - $19.25
- Target Price
- $16.00
- ROA (TTM)
- 41.19%
- ROE (TTM)
- 52.54%
- Avg. Volume (1M)
- 1M
- Avg. Volume Value (1M)
- $20.37M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
AUPH Performance Chart
Aurinia Pharmaceuticals Inc. (AUPH) is down 6.7% since the beginning of the year. At $15 per share, AUPH is trading 22.7% below its 52-week high of $19. Investors who bought $1,000 worth of AUPH shares 5 years ago would now be looking at an investment worth $1,098.
Loading charts...
Compare this symbol against anything
Returns By Period
Aurinia Pharmaceuticals Inc. (AUPH) has returned -6.71% so far this year and 41.85% over the past 12 months. Looking at the last ten years, AUPH has achieved an annualized return of 15.71%, outperforming the S&P 500 Index benchmark, which averaged 13.26% per year.
Aurinia Pharmaceuticals Inc.
- 1D
- -0.80%
- 1M
- -4.68%
- 6M
- 2.41%
- YTD
- -6.71%
- 1Y
- 41.85%
- 3Y*
- 12.50%
- 5Y*
- 1.88%
- 10Y*
- 15.71%
- ALL TIME*
- 11.66%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
AUPH Monthly Returns History
Based on dividend-adjusted daily data since Sep 3, 2014, AUPH's average daily return is +0.15%, while the average monthly return is +3.19%. At this rate, an investment would double in approximately 1.8 years.
Historically, 51% of months were positive and 49% were negative. The best month was Dec 2019 with a return of +155.2%, while the worst month was Nov 2021 at -43.1%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.
On a daily basis, AUPH closed higher 47% of trading days. The best single day was Dec 5, 2019 with a return of +78.8%, while the worst single day was Aug 15, 2016 at -55.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.90% | -2.48% | 4.59% | 3.81% | -0.36% | 10.70% | -12.32% | -6.71% | |||||
| 2025 | -11.47% | 0.00% | 1.13% | 2.49% | -4.85% | 8.04% | 9.15% | 29.69% | -7.84% | 19.19% | 22.40% | -1.05% | 77.62% |
| 2024 | -16.13% | -24.14% | -12.41% | 1.60% | 6.48% | 5.35% | 2.98% | 15.82% | 7.64% | -1.64% | 22.88% | 1.35% | -0.11% |
| 2023 | 109.49% | 0.44% | 20.57% | 2.65% | -20.36% | 8.04% | 19.63% | -21.68% | -14.33% | -5.53% | 17.71% | 4.05% | 108.10% |
| 2022 | -27.15% | -26.17% | 0.65% | -16.88% | 9.62% | -10.90% | -18.61% | -10.02% | 2.17% | 8.11% | -36.90% | -15.79% | -81.11% |
| 2021 | 20.82% | -16.22% | -7.25% | 2.19% | 9.42% | -10.74% | 4.63% | 20.06% | 35.93% | 49.48% | -43.05% | 21.39% | 65.37% |
Benchmark Metrics
Aurinia Pharmaceuticals Inc. has an annualized alpha of 29.81%, beta of 0.88, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since September 03, 2014.
- This stock participated in 128.56% of S&P 500 Index downside but only 127.07% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 29.81%
- Beta
- 0.88
- R²
- 0.05
- Upside Capture
- 127.07%
- Downside Capture
- 128.56%
Return for Risk
Risk / Return Rank
AUPH ranks 84 for risk / return — above 84% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Aurinia Pharmaceuticals Inc. (AUPH) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AUPH | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.01 | ||
| Sortino ratioReturn per unit of downside risk | +0.05 | ||
| Omega ratioGain probability vs. loss probability | 1.28 | 1.25 | +0.02 |
| Calmar ratioReturn relative to maximum drawdown | 3.05 | 2.00 | +1.05 |
| Martin ratioReturn relative to average drawdown | 7.13 | 8.49 | -1.36 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Aurinia Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Aurinia Pharmaceuticals Inc. was 87.58%, occurring on Dec 27, 2022. The portfolio has not yet recovered.
The current Aurinia Pharmaceuticals Inc. drawdown is 55.02%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-87.58%Dec 2022 | 1y 1mo | — | 4y 9moNov 2021 - now | Bear market2022 |
-67.17%Jan 2016 | 10mo 1d | 1y 1mo | 1y 11moMar 2015 - Mar 2017 | — |
-63.19%Oct 2019 | 2y 7mo | 1mo 22d | 2y 8moMar 2017 - Dec 2019 | — |
-53.40%May 2021 | 1y 4mo | 4mo 7d | 1y 8moJan 2020 - Sep 2021 | — |
-27.75%Oct 2014 | 1mo 10d | 15d | 1mo 25dSep 2014 - Oct 2014 | — |
Drawdown Indicators
| AUPH | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -87.58% | -56.78% | -30.80% |
Max Drawdown (1Y)Largest decline over 1 year | -20.09% | -9.10% | -10.99% |
Max Drawdown (3Y)Largest decline over 3 years | -54.45% | -18.90% | -35.55% |
Max Drawdown (5Y)Largest decline over 5 years | -87.58% | -25.43% | -62.15% |
Max Drawdown (10Y)Largest decline over 10 years | -87.58% | -33.92% | -53.66% |
Current DrawdownCurrent decline from peak | -55.02% | -1.58% | -53.44% |
Average DrawdownAverage peak-to-trough decline | -49.23% | -10.70% | -38.53% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.57% | 2.14% | +6.43% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Aurinia Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Aurinia Pharmaceuticals Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for AUPH, comparing it with other companies in the Biotechnology industry. Currently, AUPH has a P/E ratio of 6.9. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for AUPH compared to other companies in the Biotechnology industry. AUPH currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AUPH relative to other companies in the Biotechnology industry. Currently, AUPH has a P/S ratio of 6.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AUPH in comparison with other companies in the Biotechnology industry. Currently, AUPH has a P/B value of 3.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with AUPH
Add Aurinia Pharmaceuticals Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with AUPH